/
CANF
$3.36-$0.04 (-1.16%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.4M
2M shares
52-week range
$2.56 – $13.80
7% from low
Exchange
XASE
ADRC
Change$-378.60
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
www.canfite.com- Employees
- 5
- IPO / List date
- Sep 10, 2012
Held by traders on TradeandTell
No one on the platform currently holds CANF.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CANF as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-01-05 | 1-for-20reverse |
| 2023-01-09 | 1-for-10reverse |
| 2019-05-10 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded CANF yet.
